您的购物车当前为空
别名 Ferroptosis IN8
Ferroptosis-IN-8 是一种有效且特异性的铁死亡小分子抑制剂,其半数抑制浓度(IC50)为40.49 nM。它通过强大的抗氧化机制抑制RSL3或FIN56诱导的铁死亡,减轻肝肾损伤模型中的症状,并在预防一系列铁死亡相关疾病方面显示出巨大潜力。


为众多的药物研发团队赋能,
让新药发现更简单!
Ferroptosis-IN-8 是一种有效且特异性的铁死亡小分子抑制剂,其半数抑制浓度(IC50)为40.49 nM。它通过强大的抗氧化机制抑制RSL3或FIN56诱导的铁死亡,减轻肝肾损伤模型中的症状,并在预防一系列铁死亡相关疾病方面显示出巨大潜力。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,300 | In Stock | |
| 5 mg | ¥ 3,250 | In Stock | |
| 10 mg | ¥ 4,730 | In Stock | |
| 25 mg | ¥ 7,490 | In Stock | |
| 50 mg | ¥ 9,870 | In Stock | |
| 100 mg | ¥ 13,600 | In Stock | |
| 200 mg | ¥ 18,300 | In Stock |
Ferroptosis-IN-8 相关产品
| 产品描述 | Ferroptosis-IN-8 (Compound B4) is a potent and specific small molecule inhibitor of ferroptosis, demonstrating a half-maximal inhibitory concentration (IC50) of 40.49 nM. it suppresses RSL3- or FIN56-induced ferroptosis through robust antioxidant mechanisms, alleviates models of hepatorenal injury, and shows significant potential in preventing a spectrum of ferroptosis-related diseases. |
| 靶点活性 | Ferroptosis:40.49 nM |
| 体内活性 | 方法:Ferroptosis-IN-8(10 mg/kg,腹腔注射)处理对乙酰氨基酚诱发的急性肝损伤小鼠模型,观察其治疗效果。 |
| 别名 | Ferroptosis IN8 |
| 分子量 | 285.3 |
| 分子式 | C15H15N3O3 |
| CAS No. | 3056016-82-8 |
| Smiles | O=C(NN=CC1=CC=C(OC)C=C1)C=2C=CC=C(O)C2N |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 40 mg/mL (140.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容